Skip to NavigationSkip to content

Black Swan Analysis Epiomic™ Epidemiology Forecast Report on Aortic Stenosis in 16 Major Markets - ref #BS000023

Black Swan Analysis Epiomic™ Epidemiology Forecast Report on Aortic Stenosis in 16 Major Markets

Aortic Stenosis (AS) is the occlusion or loss of aortic valve surface area resulting in stenosis of the aortic valve. Currently, AS is thought to be the most common form of valvular heart disease in Western countries. This report provides the current prevalent population for AS across 16 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan, Turkey, Mexico, Canada, Australia, Finland, Poland, Argentina and China) split by gender and 5-year age cohort. Along with the current prevalence, the report provides an overview of the risk factors, aetiology, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of AS have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Aortic Stenosis include:

  • Previous myocardial infarct / Angina
  • Carotid atherosclerosis
  • COPD
  • Lower limb atherosclerosis
  • Atrial fibrillation
  • Heart failure

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in global AS’s market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of AS and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on AS’s prevalent population.
  • Identify sub-populations within AS which require treatment.
  • Gain an understanding of the specific markets that have the largest number of AS patients.

Publisher: Black Swan
Publication date: November 2015

Price: £ 3,950.00

You need to agree to the Terms and Conditions before placing your order

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches